Pacer Advisors Inc. Buys Shares of 1,563,040 BioCryst Pharmaceuticals, Inc. $BCRX

Pacer Advisors Inc. purchased a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 1,563,040 shares of the biotechnology company’s stock, valued at approximately $14,880,000.

A number of other hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. increased its position in BioCryst Pharmaceuticals by 2.2% in the 4th quarter. Vanguard Group Inc. now owns 22,273,375 shares of the biotechnology company’s stock valued at $173,732,000 after acquiring an additional 482,494 shares during the period. RA Capital Management L.P. acquired a new position in BioCryst Pharmaceuticals during the 4th quarter worth $123,452,000. Deerfield Management Company L.P. grew its stake in shares of BioCryst Pharmaceuticals by 159.4% in the third quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock worth $92,363,000 after purchasing an additional 7,477,000 shares in the last quarter. State Street Corp grew its stake in shares of BioCryst Pharmaceuticals by 12.9% in the fourth quarter. State Street Corp now owns 11,073,211 shares of the biotechnology company’s stock worth $86,371,000 after purchasing an additional 1,265,773 shares in the last quarter. Finally, Janus Henderson Group PLC increased its holdings in shares of BioCryst Pharmaceuticals by 20.3% during the first quarter. Janus Henderson Group PLC now owns 8,908,506 shares of the biotechnology company’s stock valued at $84,854,000 after purchasing an additional 1,504,120 shares during the period. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Performance

NASDAQ BCRX opened at $9.02 on Wednesday. The firm’s 50 day moving average price is $9.32 and its two-hundred day moving average price is $8.67. BioCryst Pharmaceuticals, Inc. has a twelve month low of $6.00 and a twelve month high of $11.22. The stock has a market cap of $2.29 billion, a price-to-earnings ratio of -5.07 and a beta of 0.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing the consensus estimate of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The business had revenue of $156.41 million during the quarter, compared to analyst estimates of $151.12 million. During the same period last year, the business earned $0.20 EPS. The business’s quarterly revenue was up 7.5% on a year-over-year basis. On average, research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -2.58 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Cantor Fitzgerald upped their price objective on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Tuesday, June 30th. Royal Bank Of Canada boosted their price target on shares of BioCryst Pharmaceuticals from $13.00 to $14.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. Weiss Ratings reiterated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. Wedbush cut their target price on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, June 30th. Eight analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $20.80.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.